• genetrackhealthcare@gmail.com
  • +91 9311400585

FAQ

Cancer Screening

Cancer genetic screening identifies inherited genetic variants associated with increased cancer risk, enabling early risk assessment, surveillance planning, and preventive care.

The test supports risk stratification and preventive oncology by identifying individuals who may have a higher inherited predisposition to specific cancers.

This test is suitable for:

  • Individuals with a family history of cancer
  • Early-onset cancer cases
  • Individuals with multiple cancers
  • Preventive health and high-risk screening programs

Panels commonly include genes associated with breast, ovarian, colorectal, prostate, pancreatic, gastric, and other hereditary cancers, depending on the panel design.

The test evaluates a curated set of clinically relevant cancer-predisposition genes, selected based on guideline relevance, penetrance, and clinical actionability.

Testing is performed using peripheral blood or buccal swab samples, allowing flexible clinical implementation.

Cancer screening is conducted using validated next-generation sequencing (NGS) platforms, ensuring high sensitivity and specificity for pathogenic variant detection.

Reports include:

  • Pathogenic / likely pathogenic variant status
  • Gene-specific findings
  • Clear, clinician-oriented summaries
  • Guidance for referral and follow-up

No. Cancer genetic screening is a risk-assessment and preventive tool. It does not diagnose cancer.

The test supports:

  • Preventive oncology programs
  • Surveillance and screening strategy planning
  • Family cascade testing decisions

Cancer genetic screening integrates into:

  • Oncology and preventive care clinics
  • High-risk cancer programs
  • Multidisciplinary tumor boards
  • Family history and cascade screening pathways

Carrier Screening

Carrier screening is a genetic test that identifies individuals who carry pathogenic variants for inherited disorders that may be passed on to offspring, even if the individual is asymptomatic.

Carrier screening is recommended for:

  • Couples planning pregnancy
  • Couples undergoing IVF/ART
  • Individuals with a family history of genetic disorders

The panel includes autosomal recessive and X-linked genetic disorders, commonly associated with pediatric, metabolic, neurological, and hematological conditions.

The test evaluates a curated panel of clinically significant genes, selected based on disease severity, carrier frequency, and relevance to reproductive risk assessment.

Carrier screening is performed using peripheral blood, enabling flexible collection in both clinical and outreach settings.

The test uses validated next-generation sequencing (NGS)–based methods to ensure high analytical accuracy and reproducibility.

Results are reported as:

  • Carrier / Non-carrier status
  • Clear gene and condition identification
  • Clinician-friendly summaries suitable for counseling

No. Carrier screening is a risk-assessment and reproductive planning tool. It does not diagnose disease in the tested individual.

The test supports:

  • Preventive oncology programs
  • Surveillance and screening strategy planning
  • Family cascade testing decisions

Yes. If one partner is identified as a carrier, testing of the reproductive partner can be recommended as part of standard clinical workflow.

Gut Microbiome

Gut microbiome genomic testing profiles the taxonomic composition and functional potential of gut microorganisms. For clinicians/dietitians, it enables data-driven nutritional interventions by linking microbial patterns with digestion, metabolic function, inflammation, and nutrient metabolism.

The test typically utilizes next-generation sequencing (NGS), either 16S rRNA gene sequencing or shotgun metagenomic sequencing.

Results are reported at the genus level, ensuring analytical reliability while remaining clinically meaningful for nutrition and lifestyle guidance.

A stool sample collected using a standardized collection kit.

Microbiome data allows dietitians to personalize:

  • Fiber type and quantity (soluble vs insoluble)
  • Prebiotic and probiotic selection
  • Macronutrient distribution
  • Food tolerance strategies
  • Anti-inflammatory and gut-healing protocols

The test can support nutritional strategies for conditions such as IBS, functional bloating, metabolic syndrome, insulin resistance, obesity, and chronic low-grade inflammation, while remaining non-diagnostic.

Yes. Reports often include dysbiosis indices, beneficial vs opportunistic bacteria ratios, and microbial imbalance markers to help guide corrective dietary interventions.

The analysis is based on peer-reviewed microbiome reference databases and validated bioinformatics pipelines. Results should be interpreted alongside clinical history, dietary assessment, and biochemical parameters.

Dietitians should account for recent antibiotic use, probiotics, prebiotics, dietary changes, medications, and GI infections, as these can significantly influence microbial composition.

Yes. Reports are designed to be structured, visual, and clinically interpretable, allowing dietitians to translate complex microbiome data into practical nutritional recommendations for clients.

Yes. Repeat testing can be used to monitor response to dietary interventions, lifestyle modifications, and gut-focused protocols over time.

The test is suitable for:

  • Clinical nutrition and dietetics practices
  • Functional and integrative medicine clinics
  • Preventive health and wellness centers
  • Hospitals and diagnostic partners

The test acts as a decision-support tool, enhancing intake assessments, strengthening client education, improving compliance, and differentiating dietitian-led personalized nutrition services.

Yes. The test can be applied in clinical nutrition, functional medicine, sports nutrition, weight management, and preventive wellness programs.

Yes. Genique offers facility from pickup of the sample till the report is generated and sent to you. This includes designing and structuring of report and its design there after analysing samples to get accurate results and delivering it all in dedicated TAT.

No. The test is non-diagnostic and intended as a clinical decision-support tool. All findings must be interpreted by qualified healthcare professionals.

Pharmacogenomics

Pharmacogenomics testing evaluates genetic variants that influence drug metabolism, transport, and target response. It supports personalized prescribing by identifying variability in efficacy, toxicity risk, and dose requirements across commonly prescribed medications.

Testing is performed using non-invasive buccal swabs or peripheral blood samples, with DNA extraction followed by targeted genotyping or sequencing.

The test employs validated NGS or PCR-based genotyping platforms, ensuring high analytical sensitivity, specificity, and reproducibility for clinically relevant variants.

PGx testing supports optimized prescribing in:

  • Psychiatry (antidepressants, antipsychotics)
  • Cardiology (antiplatelets, anticoagulants, statins)
  • Pain management (opioids, NSAIDs)
  • Oncology supportive care
  • Infectious diseases
  • Gastroenterology

Yes. By identifying high-risk genotypes, PGx testing helps minimize ADRs, avoid therapeutic failure, and reduce trial-and-error prescribing.

Results can be used longitudinally across a patient’s lifetime, supporting multiple prescriptions and reducing repeat testing, especially in chronic disease management.

No. PGx testing is a decision-support tool that complements clinical evaluation, patient history, and therapeutic monitoring. Final prescribing decisions remain with the clinician.

The mapping of phenotypes to drugs, dosages, interpretation, and recommendations are obtained from the CPIC, FDA, PharmGKB or DPWG guideline publications
img
Book Appointment

We Are open And Welcoming Patients

Book Appointment
WhatsApp